Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGAV | P06756 | 8/20 | 0.39 |
| ▸ | ITGB3 | P05106 | 4/20 | 0.38 |
| ▸ | ITGA2B | P08514 | 4/20 | 0.38 |
| ▸ | CASP1 | P29466 | 1/20 | 0.37 |
| ▸ | FDPS | P14324 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.36 |
| ▸ | KDM6B | O15054 | 1/20 | 0.36 |
| ▸ | FTO | Q9C0B1 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2116269 | 0.89 | FDPS (0.39) | FDPSGAA | |
| Hydrochloric Acid SCHEMBL2116377 | 0.89 | FDPS (0.38) | FDPSGAA | |
| SCHEMBL27801367 | 0.87 | CASP1 (0.36) | ITGAVITGB3ITGA2BCASP1FDPS | |
| SCHEMBL27801369 | 0.86 | CASP1 (0.36) | ITGAVITGB3ITGA2BCASP1FDPS | |
| SCHEMBL2119125 | 0.78 | FDPS (0.42) | FDPSGAA | |
| Hydrochloric Acid SCHEMBL2119121 | 0.78 | FDPS (0.42) | FDPSGAA | |
| Ammonia Solution, Strong SCHEMBL2117519 | 0.76 | GAA (0.36) | FDPSGAAKDM6BFTO | |
| SCHEMBL2116667 | 0.74 | CA12 (0.38) | CASP1FDPS | |
| SCHEMBL2116709 | 0.74 | HDAC8 (0.39) | FDPSGAAKDM6BFTO | |
| SCHEMBL2115818 | 0.74 | KYNU (0.45) | CASP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2250152-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | Novartis AG (CH) | 2010-11-17 | — | — | EP | claimed |
| WO-2009106586-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2009-09-03 | — | — | WO | claimed |
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | NOVARTIS AG (CH) | 2012-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120094958-A1 | QUINOLINES AS INHIBITORS OF FARNESYL PYROPHOSPHATE SYNTHASE | FDPS, GGPS1, CTPS1 | ITGAV 4834/4885ITGB3 4762/4885ITGA2B 4719/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.